Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A new preclinical study reports that atovaquone, an approved antiparasitic drug, was reformulated into lactoferrin-based ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE)-- "Next Generation Complement Therapeutics Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global next-generation complement ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Repurposing complement inhibitors to see whether they are effective against neurodegenerative diseases is already in development. (Artur Plawgo/iStock/Getty Images Plus) With Alzheimer’s disease ...

GA treatment options in various steps in FDA approval process are discussed by a panel of medical experts. Ryan Haumschild, PharmD, MS, MBA: We’ve given a background of geographic atrophy [GA], but ...

Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, ...